Baseline Amino Acid Substitutions in the NS5A ISDR and PKR Binding Domain of Hepatitis C and Different Fibrosis Levels and Levels of Development of Hepatocellular Carcinoma in Patients Treated with DAAs

Variations in the interferon sensitivity-determining region (ISDR) within the NS5A region were related to the development of hepatocellular carcinoma (HCC) in patients infected with hepatitis C virus (HCV). The aim of the study was to investigate a relationship between ISDR/PKR substitutions and their association with liver fibrosis or HCC development. A total of 316 patients infected with HCV and treated with DAAs were evaluated. HCV RNA was quantified and sequenced before treatment. The liver fibrosis stage was assessed by transient elastography and equalized to METAVIR scores. Multivariate analysis showed that ≥3 substitutions in ISDR and ≥6 in PKR-bd were significantly associated with advanced fibrosis. Advanced fibrosis was observed in patients with higher substitutions in ISDR and PKR-bd. A higher correlation between advanced fibrosis and a high frequency of ≥3 substitutions in ISDR and ≥6 in PKR-bd was observed in patients infected with genotype 2c. In addition, in a higher proportion of HCC patients, advanced fibrosis (40.4% vs. 88.2%; p < 0.001) and ≥6 substitutions in PKR-bd (15.4% vs. 41.2%; p = 0.01) was observed. In conclusion, a higher number of substitutions in ISDR and PKR-bd were associated with advanced liver fibrosis, suggesting a use of like predictors for progression in the liver damage. A significantly higher number of PKR-bd substitutions was observed in HCC patients; in particular, in patients infected with HCV genotype 2c.

[1]  M. Milella,et al.  Real‐life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[2]  R. Sacco,et al.  Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis , 2019, Expert opinion on drug safety.

[3]  Takanori Ito,et al.  Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Who Achieved Sustained Virologic Response. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  H. El‐Serag,et al.  Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents , 2019, Digestive Diseases and Sciences.

[5]  K. Kerr,et al.  Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. , 2018, Journal of hepatology.

[6]  Manal M. Hassan,et al.  Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer , 2018, Journal of hepatocellular carcinoma.

[7]  K. Hayashi,et al.  Substitutions in interferon sensitivity‐determining region and hepatocarcinogenesis after hepatitis C virus eradication , 2018, Journal of gastroenterology and hepatology.

[8]  Francesca Ceccherini-Silberstein,et al.  Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. , 2018, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[9]  Hussein H. Aly,et al.  Interferon sensitivity-determining region of hepatitis C virus influences virus production and interferon signaling , 2015, Oncotarget.

[10]  F. Baldanti,et al.  Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs , 2017, Scientific Reports.

[11]  J. Salmerón,et al.  Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment , 2017, World journal of gastroenterology.

[12]  J. A. Patino-Galindo,et al.  Comparative analysis of variation and selection in the HCV genome. , 2017, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[13]  Jean-Michel Pawlotsky,et al.  Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. , 2016, Gastroenterology.

[14]  Christoph Sarrazin,et al.  The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. , 2016, Journal of hepatology.

[15]  P. Saliou,et al.  Duplication of the V3 domain in hepatitis C virus (1b) NS5A protein: Clonal analysis and physicochemical properties related to hepatocellular carcinoma occurrence. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  Takanori Ito,et al.  Risk factors of hepatocellular carcinoma development in non‐cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection , 2015, Journal of gastroenterology and hepatology.

[17]  M. Manns,et al.  Is there sufficient evidence to recommend antiviral therapy in hepatitis C? , 2014, Journal of hepatology.

[18]  O. Weiland,et al.  A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Y. Hiasa,et al.  Protein Kinase R Modulates c-Fos and c-Jun Signaling to Promote Proliferation of Hepatocellular Carcinoma with Hepatitis C Virus Infection , 2013, PloS one.

[20]  H. Nomura,et al.  Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. , 2013, Journal of hepatology.

[21]  F. Baldanti,et al.  Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients , 2012, Virology Journal.

[22]  A. Moya,et al.  The role of positive selection in hepatitis C virus. , 2009, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[23]  M. Mondelli,et al.  Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. , 2009, Journal of hepatology.

[24]  T. Hu,et al.  Association of amino acid variations in the NS5A and E2‐PePHD region of hepatitis C virus 1b with hepatocellular carcinoma , 2007, Journal of viral hepatitis.

[25]  Subash Das,et al.  Insertion and deletion analyses identify regions of non-structural protein 5A of Hepatitis C virus that are dispensable for viral genome replication. , 2006, The Journal of general virology.

[26]  J. Bruix,et al.  High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV‐1b–related cirrhosis , 2001, Hepatology.

[27]  R. Silverman,et al.  RNA-Dependent Protein Kinase PKR Is Required for Activation of NF-κB by IFN-γ in a STAT1-Independent Pathway1 , 2001, The Journal of Immunology.

[28]  B. Williams,et al.  The protein kinase PKR is required for p38 MAPK activation and the innate immune response to bacterial endotoxin , 2000, The EMBO journal.

[29]  M. Sata,et al.  Histologic Improvement of Fibrosis in Patients with Hepatitis C Who Have Sustained Response to Interferon Therapy , 2000, Annals of Internal Medicine.

[30]  S. Polyak,et al.  Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon‐sensitive virus replication , 1999, Hepatology.

[31]  Michael G. Katze,et al.  Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation , 1998, Molecular and Cellular Biology.